What PCOS Questions Should You Ask Your Doctor?

Polycystic ovary syndrome (PCOS) is a hormonal and metabolic condition, not a purely reproductive one. It is diagnosed clinically using the Rotterdam criteria (two of three features: irregular or absent ovulation, signs of excess androgens, and polycystic-appearing ovaries on ultrasound), and it carries downstream risks for insulin resistance, cardiovascular disease, endometrial changes, and mental health that a short appointment often does not have time to cover fully.

The single most useful thing a PCOS-focused visit can establish is not "do I have PCOS" but "which of the four Rotterdam phenotypes do I have, and which metabolic and reproductive risks does that specific phenotype carry." PCOS diagnosis is clinical, not laboratory-only, and the same diagnosis can mean very different treatment priorities for a woman focused on fertility versus one focused on metabolic risk reduction. That distinction, more than any single lab value, is what should drive the questions below.

Why a prepared question list matters

PCOS visits are often short, and without a specific agenda the conversation tends to focus on whichever symptom feels most pressing that day, while metabolic screening or mental health questions get skipped. This is a plausible and commonly described pattern in PCOS care literature rather than a number this article can quote precisely; readers who want the exact survey figures on patient dissatisfaction or diagnostic delay should ask their clinician to point to the current international PCOS guideline directly, since we could not verify the specific percentages sometimes cited online against a confirmed primary source.

What is well established is the diagnostic framework itself. The Rotterdam criteria, developed by a joint ESHRE/ASRM consensus group, remain the standard used internationally, and the American Society for Reproductive Medicine is one of the sponsoring bodies for current PCOS practice guidance, including recommendations on ovulation induction and cycle monitoring.

Questions about diagnosis and lab work

A reasonable opening question is: "Which two of the three Rotterdam features apply to me, and which phenotype does that put me in?" There are four recognized phenotypes (combinations of anovulation, hyperandrogenism, and polycystic ovarian morphology), and the phenotype affects which risks matter most for you.

Labs commonly discussed in a PCOS workup include:

• Total and free testosterone, to assess biochemical hyperandrogenism
• DHEA-S, to help rule out an adrenal source of excess androgen
• 17-hydroxyprogesterone, to exclude non-classic congenital adrenal hyperplasia, a condition that can mimic PCOS
• TSH, to rule out thyroid dysfunction, which can also mimic PCOS symptoms
• Prolactin, to exclude hyperprolactinemia
• AMH (anti-Müllerian hormone), which some current guidance allows as an alternative to ultrasound for assessing ovarian morphology in adults, though thresholds and use vary by lab and should be discussed with your clinician rather than treated as a fixed cutoff

If a pelvic ultrasound is ordered, a useful question is: "What follicle-count threshold are you using to call this polycystic morphology?" Modern high-resolution ultrasound can detect more follicles than older equipment, and professional societies have revisited follicle-count thresholds over time to avoid over-diagnosing normal, multifollicular ovaries in younger women. Ask your clinician which threshold and probe standard they are applying, rather than assuming a single universal number.

Questions about insulin resistance and metabolic risk

Insulin resistance is common in PCOS and is not limited to women with higher body weight; it is also reported in a meaningful share of women with PCOS who are lean. A useful question is: "Has my glucose screening included an oral glucose tolerance test, or only a fasting glucose?"

Fasting glucose alone can miss postprandial glucose abnormalities that a formal oral glucose tolerance test would catch. Ask your clinician whether a fasting-only test is adequate for your risk profile, or whether a full OGTT is warranted given a PCOS diagnosis.

Other metabolic questions worth asking:

Questions about treatment options

A useful framing question is: "What is the primary goal of my treatment right now, and which option is aimed at that goal specifically?" PCOS treatment is symptom-directed; no single medication addresses menstrual irregularity, hyperandrogenism, insulin resistance, and fertility all at once.

For menstrual irregularity: Combined hormonal contraceptives are commonly used first-line for cycle regulation and androgen suppression. Different progestin components (for example, drospirenone versus levonorgestrel) have different anti-androgenic profiles, so it is reasonable to ask which formulation is being recommended and why.

For insulin resistance: Metformin is the most studied insulin-sensitizing medication used in PCOS. It is often prescribed off-label for this purpose rather than under an FDA indication specific to PCOS, and its effects on weight and insulin markers are generally modest rather than dramatic. Ask whether metformin fits your specific glucose tolerance results and what starting dose and titration schedule is planned, since gastrointestinal side effects are common and often manageable with slower titration or an extended-release formulation.

For hirsutism and acne: Spironolactone is commonly used off-label for PCOS-related hirsutism. Ask what timeline to expect before seeing visible improvement in hair growth, since anti-androgen therapy for hirsutism generally takes several months to show effect, not weeks. Topical eflornithine is another option that can be combined with systemic anti-androgen therapy for facial hirsutism specifically.

Questions about fertility and family planning

If pregnancy is a current goal, a central question is: "Are you recommending letrozole or clomiphene citrate as first-line ovulation induction?" Current specialty guidance generally favors letrozole over clomiphene citrate as first-line ovulation induction in PCOS, based on randomized trial evidence comparing live birth rates between the two agents. If you want the exact trial data behind this recommendation, ask your clinician to point you to the specific study, since we are not able to confirm precise live-birth percentages here without a verified primary source.

Other fertility questions worth asking:

• "Will you monitor my follicular response with ultrasound during ovulation induction?" Cycle monitoring is recommended to reduce the risk of higher-order multiple pregnancy, particularly with gonadotropin-based protocols.
• "Given my age and ovarian reserve, is there time for a lifestyle-first approach, or should we start medication now?" Guidance in this area generally supports attempting weight-related lifestyle changes before pharmacologic ovulation induction when time and ovarian reserve allow it, but this is a judgment call that depends on your specific age, duration of infertility, and partner factors, not a fixed rule.
• "Should I have a preconception oral glucose tolerance test, and what is the current thinking on metformin during pregnancy for reducing gestational diabetes risk in PCOS?" The evidence on metformin for gestational diabetes prevention specifically in PCOS pregnancies is mixed across trials, and this is a nuance worth discussing directly with your obstetric provider rather than assuming metformin continuation is automatically beneficial.

Questions about weight management

Weight-related conversations in PCOS deserve more specificity than general advice to eat less and move more. A useful opening question is: "Is my weight gain primarily driven by insulin resistance, and does that change which intervention you'd recommend?"

Structured lifestyle intervention, typically involving a modest calorie deficit, regular moderate-intensity exercise, and behavioral support, is commonly recommended as a first step for weight-related PCOS symptoms, with a general goal of modest body weight reduction (often described as being in the range of 5 to 10 percent) to help restore more regular ovulation in some women. Ask for a referral to a dietitian familiar with PCOS and whether your macronutrient approach should be adjusted given insulin resistance.

On GLP-1 receptor agonists: Liraglutide and semaglutide are FDA-approved for chronic weight management in adults meeting BMI criteria (generally BMI ≥30, or ≥27 with a weight-related comorbidity such as insulin resistance). Neither is FDA-approved specifically for PCOS; their use in PCOS for weight and metabolic benefit is an extension of their general weight-management indication rather than a PCOS-specific approval, so ask your clinician to be explicit about which indication applies to your situation and what monitoring is planned.

Questions about mental health

Anxiety and depression are reported at meaningfully higher rates in women with PCOS compared with the general population across multiple studies, even though the exact multiplier varies by study design and population. A direct question worth asking is: "Are you screening me for depression and anxiety as part of my PCOS care, and with which tool?"

Validated screening tools such as the PHQ-9 (depression) and GAD-7 (anxiety) are commonly recommended for use at diagnosis and at intervals thereafter in current PCOS guidance. If your clinician has not offered this, it is reasonable to ask for it directly, along with a referral pathway if your score is elevated.

Disordered eating is also reported more frequently in women with PCOS. If you are being advised to start a calorie-restricted diet, it is reasonable to ask whether you should be screened for disordered eating first, since starting a restrictive diet without that screening can worsen an existing eating pattern that has not been identified.

Questions about long-term monitoring

PCOS is a lifelong condition, and its metabolic risks do not resolve after menopause. A useful long-term question is: "What is my monitoring schedule for the next several years, and what should I expect at each visit?"

Endometrial protection is often overlooked. Chronic anovulation without periodic progesterone exposure allows the uterine lining to build up under unopposed estrogen, which raises the risk of endometrial hyperplasia over time. If you are going long stretches without a period, ask directly how your endometrium is being protected, whether through cyclic progestogen, a combined hormonal contraceptive, or another approach. This is a concrete, actionable question rather than a theoretical one.

What is established, what is plausible, and what is not settled

Established: The Rotterdam diagnostic framework, the recommendation for oral glucose tolerance testing over fasting glucose alone in PCOS, the use of letrozole ahead of clomiphene citrate for first-line ovulation induction, and the recommendation to screen for anxiety and depression are all supported by specialty society guidance and are not seriously contested in current practice.

Plausible but not fully settled for every reader: The exact numeric thresholds sometimes quoted online (specific percentages for prevalence, diagnostic delay, or effect sizes of individual medications) vary across studies and populations, and this article intentionally avoids presenting a single precise figure as universal. Ask your own clinician for the specific numbers behind any recommendation that affects your decision.

Not established: There is no evidence that any specific question list itself changes clinical outcomes. The value of preparing questions is a reasonable inference from how limited visit time is typically structured, not a tested intervention with its own trial data.

A decision framework: which questions to prioritize based on your goal

Not every question above fits every visit. Use your primary goal right now to pick the three or four questions that matter most, and treat the rest as background for a future visit.

If you are going more than roughly three months without a period and have not discussed endometrial protection, or if you have new heavy bleeding, severe pelvic pain, or symptoms suggesting a pregnancy complication, treat that as a reason to seek care sooner rather than waiting for a routine follow-up.

A note on sourcing for this draft: Several precise statistics and two attributed quotations from the prior version of this article could not be verified against a confirmed primary source and have been removed or converted to general, unlinked statements pending editorial and clinical review. Readers and reviewers who need exact figures on prevalence, diagnostic delay, or specific trial outcomes should verify those numbers against the current international PCOS guideline and the original trial publications directly before they are restored to this page.